In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Serum endocan levels in patients with cardiac syndrome x

Session Poster session 1

Speaker Suleyman Cagan Efe

Event : ESC Congress 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease (Chronic)
  • Session type : Poster Session

Authors : S Efe (agri,TR), K Demirci (Istanbul,TR), S Ozturk (istanbul,TR), S Gurbuz (Eskisehir,TR), A Kilicgedik (Istanbul,TR), C Kirma (Istanbul,TR)

Authors:
S. Efe1 , K. Demirci2 , S. Ozturk3 , S. Gurbuz4 , A. Kilicgedik2 , C. Kirma2 , 1Agri State Hospital, Cardiology - Agri - Turkey , 2Kartal Kosuyolu Heart and Research Hospital - Istanbul - Turkey , 3Haseki Researh and Training Hospital, Cardiology - Istanbul - Turkey , 4Yunus Emre Government Hospital - Eskisehir - Turkey ,

Citation:
European Heart Journal ( 2017 ) 38 ( Supplement ), 193

Background: Endocan is recently introduced marker of endothelial dysfunction and associated with inflammation, endothelial dysfunction, and atherosclerosis. The relationship between cardiac syndrome X (CSX) and endocan has not been evaluated. The objective of this study was to compare serum endocan levels with CSX patients and control subjects.

Patients and methods: In this study, 50 patients were included in the CSX group, and 28 patients formed the control group. Patients with pathological conditions that could potentially influence endothelial functions were excluded. Endocan serum concentrations were measured using an enzyme-linked immunosorbent assay.

Results: The mean endocan level of the CSX group was significantly higher than that of the control group (3051,3±1900,5 ng/L vs. 2088,1±522,2 ng/L; p=0,002). There was no difference between two groups in terms of age, gender, hypertention (HT), diabetis mellitus (DM) , dislipidemia (DL) and smoking status. In ROC analysis, endocan level greater than 2072 ng/L had 72% sensitivity and 54% specificity (p=0.002) for accurately predicting CSX diagnosis.

Conclusion: The results of this study suggest that patients with CSX have higher endocan levels than control group. Therefore it may be valuable in uncover the underlying pathogenesis patients with CSX

Table 1. Demographical properties of subjects
Cardiac syndrome X (n=50)Control group (n=28)p value
Age (year)44,1±12,142,1±12,20,98
Sex (male)24 (%48)19 (%67,9)0,09
Dislipidemia10 (%20)5 (%17,9)0,81
Diabetes mellitus9 (%18)5 (%17,9)0,99
Hypertension13 (%26)7 (%25)0,92
Smoking16 (%32)9 (%32,1)0,99
Endocan3051,3±1900,52088,1±522,20,002
Serum endocan levels between subjects

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are